Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
DALLAS--(BUSINESS WIRE)--Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. (NASDAQ: LTRN), today announced that the U.S. Food and Drug Administration (FDA) has cleared its In...
What is the expected cost of the Phase Ib/2a trial and its impact on Lantern Pharma’s cash runway and financing needs?
How might the partnership or licensing structure (if any) for STAR‑001 affect future revenue streams or margin assumptions?
Will the trial results be disclosed in upcoming investor presentations or conference calls, and what impact could that have on market perception?
19 days ago